# Paul McCreadie

> Paul McCreadie is a Series D investor at Arboretum Ventures backing Health Care and Medical. See 11 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Arboretum Ventures](https://shizune.co/investors/profile/arboretum-ventures)
- Location: Detroit, United States
- Total investments: 11
- Last investment: Jun 2025
- Lead investor: 55%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/in/paulmccreadie

Paul McCreadie is a Series D investor at Arboretum Ventures in Detroit focused on Health Care and Medical. Paul McCreadie is based out of Ann Arbor, Michigan and is the Managing Partner & COO of Arboretum Ventures. Paul previously worked at Cardiac Dimensions as a Board Member. Paul McCreadie attended the University of Michigan Ross School of Business.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 8 | 73% |
| Medical | 5 | 45% |
| Biotechnology | 3 | 27% |
| Pharmaceutical | 3 | 27% |
| Medical Device | 2 | 18% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series D | 3 | 27% |
| Series C | 2 | 18% |
| Series A | 1 | 9% |
| Series B | 1 | 9% |
| Funding Round | 1 | 9% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 7 | 64% |
| Israel | 1 | 9% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Allay Therapeutics | Allay Therapeutics offers analgesic products for post-surgical pain management and recuperation. The company was founded in 2017 and is headquartered in Menlo Park, California, United States. | $57.5M | Series D | Jun 05, 2025 |  |
| Orasis Pharmaceuticals | Orasis Pharmaceuticals develops a corrective eye drop to treat presbyopia. The company's product, CSF-1, is an eye drop that improves the quality of life for people with presbyopia by alleviating the burden of reading glasses. By repurposing existing and well-studied molecules, CSF-1 is designed to be effective and also safe, comfortable, andeasy-to-use. | $68M | Series D | Oct 08, 2024 |  |
| Delphinus Medical Technologies | Delphinus Medical Technologies develops, commercializes, sells, and services the breast cancer screening solutions to hospitals and imaging clinics in the United States and internationally. It commercializes SoftVue, a three-dimensional and tomographic ultrasound imaging and risk assessment device that examines women's breasts for the presenceof benign and/or malignant masses, assesses breast cancer risks, diagnoses breast diseases, and monitors therapy. The company was founded in 2009 and is based in Detroit, Michigan. | $30.4M | Series D | Sep 13, 2022 |  |
| Allay Therapeutics | Allay Therapeutics offers analgesic products for post-surgical pain management and recuperation. The company was founded in 2017 and is headquartered in Menlo Park, California, United States. | $60M | Series C | Sep 15, 2021 |  |
| BioIQ | BioIQ also known as Jentryx is a health improvement technology company that has implemented the industry’s first integrated, customizable and measurable approach to optimizing investments in corporate health and wellness programs. The company’s unique health screening platform, ecosystem of health improvement tools, and proven methodology forobtaining quantifiable wellness insights are serving beneficiaries across the United States. BioIQ works with some of the largest employers and health companies in the nation and has launched over 3,000 successful health improvement programs since its inception in 2005. | $26.5M |  | Mar 22, 2018 |  |
| ArborMetrix | ArborMetrix is a performance measurement for Acute and Specialty Care. Based on its industry-changing research, ArborMetrix delivers outcomes-based, risk- and reliability-adjusted clinical intelligence, which provides actionable insights for Hospitals, Health Plans, ACOs, Physicians, Societies, and Collaboratives. Their leading healthcareanalytics solutions are proven to deliver targeted, clinically-deep insights that improve clinical outcomes, optimize financial performance, increase stakeholder value, and measure the real-world effectiveness of treatments and procedures, as well as medical device technologies and pharmaceuticals.It was founded in 2011 and headquartered in Ann Arbor, Michigan. | $6.9M | Series B | Mar 31, 2016 |  |
| RethinkFirst | Rethink Autism's solution is a web-based autism treatment platform that combines a proven treatment methodology (ABA) with a proven method of instruction (video modeling). Using technology to deliver clinical best practice treatment programs anywhere, Rethink Autism has created a unique online service providing parents and organizations withtraining for implementing treatment, tools for evaluating an individual child's needs, a comprehensive video-based curriculum with 1,200+ teaching steps, data tracking systems for measuring progress and automating case management, and online professional support. No other product or company combines a dynamic video-based curriculum, data management tools and professional support, all on a single easy-to-use web-based platform. | $10M | Series C | Aug 18, 2014 |  |
| Adavium | Adavium Medical is a medical equipment and diagnostics company aimed at bringing commercial sophistication to a highly fragmented market. The Company was formed with the intent to commercialize the most innovative portfolio of medical device and diagnostics products in Brazil. Adavium Medical portfolio today is made up of products that wecommercialize on behalf of leading international companies.Adavium Medical assembled an experienced team of more than 300 employees that ensure that its fully-integrated commercial platform operates at world-class standards.Adavium Medical have the largest customer base across premium and “long tail” customers of any medical equipment and/or diagnostics company in Brazil, with more than 2,500 customers respectively in medical equipment and diagnostics. This is exponentially more than the average distributor or multinational in the region.The company was founded in 2011 and is headquartered in Sao Paulo, Brazil. | $20M | Private Equity | Sep 04, 2013 |  |
| ArborMetrix | ArborMetrix is a performance measurement for Acute and Specialty Care. Based on its industry-changing research, ArborMetrix delivers outcomes-based, risk- and reliability-adjusted clinical intelligence, which provides actionable insights for Hospitals, Health Plans, ACOs, Physicians, Societies, and Collaboratives. Their leading healthcareanalytics solutions are proven to deliver targeted, clinically-deep insights that improve clinical outcomes, optimize financial performance, increase stakeholder value, and measure the real-world effectiveness of treatments and procedures, as well as medical device technologies and pharmaceuticals.It was founded in 2011 and headquartered in Ann Arbor, Michigan. | $7M | Series B | Jul 16, 2013 |  |
| ArborMetrix | ArborMetrix is a performance measurement for Acute and Specialty Care. Based on its industry-changing research, ArborMetrix delivers outcomes-based, risk- and reliability-adjusted clinical intelligence, which provides actionable insights for Hospitals, Health Plans, ACOs, Physicians, Societies, and Collaboratives. Their leading healthcareanalytics solutions are proven to deliver targeted, clinically-deep insights that improve clinical outcomes, optimize financial performance, increase stakeholder value, and measure the real-world effectiveness of treatments and procedures, as well as medical device technologies and pharmaceuticals.It was founded in 2011 and headquartered in Ann Arbor, Michigan. | $7M | Series B | Jul 16, 2013 |  |

10 of 11 investments shown.

## Co-investors
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 4 deals together
- [RPM Ventures](https://shizune.co/investors/profile/rpm-ventures) — VC Fund, 3 deals together
- [Beringea](https://shizune.co/investors/profile/beringea) — VC Fund, 2 deals together
- [Brandon Capital](https://shizune.co/investors/profile/brandon-capital-partners) — VC Fund, 2 deals together
- [Vertex Growth Fund](https://shizune.co/investors/profile/vertex-growth-fund) — VC Fund, 2 deals together
- [Vertex Ventures HC](https://shizune.co/investors/profile/vertex-ventures-hc) — VC Fund, 2 deals together

## About Arboretum Ventures

VC Fund · Ann Arbor, United States

Arboretum Ventures is a Michigan-based venture capital firm. It specializes in seed-stage, early-stage, mid-stage investments, and growth capital. The company seeks to invest in healthcare sector with a focus on services, medical devices, diagnostics; healthcare information technology, therapeutics, technology based healthcare services, and lifescience tools. The firm invests throughout the United States with a focus on Midwest and Michigan. It seeks to invest in companies with equity investment between $5 million and $15 million.Arboretum Ventures Jan Garfinkle in 2002 and is headquartered in Michigan.

5 contacts available at Arboretum Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Paul McCreadie | Managing Partner and Chief Operating Officer | https://shizune.co/investors/profile/paul-mccreadie |
| Robert Cesaro | Associate | https://shizune.co/investors/profile/robert-cesaro |
| Tim Petersen | Founder and Managing Partner | https://shizune.co/investors/profile/tim-petersen |
| Amanda Goldstein | Executive Assistant | https://shizune.co/investors/profile/amanda-goldstein |
| George Dunbar | Venture Partner | https://shizune.co/investors/profile/george-dunbar |

## Similar investors

### Similar stage
- [Sigma Partners](https://shizune.co/investors/profile/sigma-partners) — VC Fund
- [EDBI](https://shizune.co/investors/profile/edbi) — VC Fund
- [Trifecta Capital Advisors](https://shizune.co/investors/profile/trifecta-capital-advisors) — VC Fund

## FAQ

### What does Paul McCreadie invest in?

Paul McCreadie invests primarily in Health Care, Medical and Biotechnology startups, most often at Series D and Series C stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Paul McCreadie last invest?

The most recent investment recorded for Paul McCreadie closed in Jun 2025. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co